![](https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2022/valuestock_image_168.jpeg)
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis.
Buying $1,000 In CRSP: 5 years ago, an investor could have purchased 54.26 shares of CRISPR Therapeutics at the time with $1,000. This investment in CRSP would have produced an average annual return of 28.1%. Currently, CRISPR Therapeutics has a market capitalization of $4.69 billion.
CRISPR Therapeutics's Share Price Over Last 5 Years
![](https://www.benzinga.com/files/images/story/2022/1643137313_0.png)
This $1,000 investment would be worth $3,319.80 today based on a price of $61.28 for CRSP at the time of writing.
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
You can check out Benzinga's market data in an enhanced view on Benzinga Pro
This article was generated by Benzinga's automated content engine and reviewed by an editor.